Clinical Trial Update: Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SGLT2 inhibitors with an artificial pancreas to improve glycemic control in outpatients with type 1 diabetes; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Snippet

Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Conditions: Type1 Diabetes Mellitus | Phase 3 | Status: COMPLETED